New triple-drug combo aims to shrink esophageal tumors before surgery
NCT ID NCT07388095
First seen Feb 04, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This early-phase trial tests whether giving three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The study will enroll 22 adults aged 18-75 with stage IIA-IIIB disease who have not had prior cancer treatment. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response), with follow-up on survival and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.